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Introduction
In developing and transitional countries, in primary care 
less than 40% of patients in the public sector and 30% in 
private sector are treated in accordance with standard treat-
ment guidelines [1].  From 2911 scientific papers devoted to 
medicines published in China during the years 1990 – 2008, 
14.5% were about evaluation of medicinal remedies from 
pharmaco-therapeutic group A – Alimentary tract and me-
tabolism [2].  There are numerous sources of evaluation data 
of drugs consumed in hospitals especially of alimentary tract 
and metabolism group that present a particular permanent 
scientific and practical interest [3-13].  Nevertheless, in the 
Republic of Moldova the analysis in Defined Daily Doses 
(DDD) as an important indicator of optimal rational use of 
drug remedies generally, and alimentary tract and metabo-
lism ones, in particular, is not studied enough and not high-
lighted by scientific research literature.
The National Scientific-Practical Centre of Emergency 
Medicine of the Republic of Moldova reorganized in 2014 
in Emergency Medicine Institute (EMI), was founded in 
1959.  Clinical Services of EMI include: Orthopedic-Trau-
matology Clinic for 150 beds, Surgery Clinic for 140 beds, 
Neurosurgery Clinic for 80 beds, Neurology Clinic for 70 
beds, Maxillo-Facial clinic for 30 beds, Urology Clinic for 
40 beds, Gynecology Clinic for 30 beds, Microsurgery Clinic 
for 30 beds, Municipal Center with 8 seats hemodialysis and 
9 beds, Clinical intensive care unit for 30 beds, in total the 
above services of the EMI include 600 beds, also include 5 
emergency medical help substations and 4 out-patient de-
partments of traumatology and orthopedics [14].
The primary aim of the study was to evaluate institution-
al representative data on alimentary tract and metabolism 
drugs utilization for five year (2009-2013) period, in accor-
dance with World Health Organization (WHO) require-
ments, projected to determine the value of Defined Daily 
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Background: Irrational use of medicines that is wasteful and harmful presents an extremely serious global problem.  In developing and transitional 
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Conclusions: The obtained data reveals that from 3 basic characteristics of drug consumption, DDD is the most objective and can be considered as the 
cornerstone for making decisions on determining the needs and organization of rational use of medicines.
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Doses per 1000 Occupied-Bed Days (DDD/1000) [15].  To 
ensure fuller study it was necessary to determine the DDD 
of medical remedies for this group of drugs which have been 
used in EMI, but that are not published by WHO.  Based on 
obtained data, it aimed to make conclusions on the use of 
alimentary tract and metabolism drugs in the medical insti-
tutions and to propose recommendations for ensuring their 
optimization.
Material and methods
For this study we used data of a five-year (2009-2013) 
period, in EMI, which show the dynamics of consumption 
of medicinal remedies from pharmaco-therapeutic group A 
– Alimentary tract and metabolism, classified as Anatomical
Therapeutic Chemical (ATC), classification system of WHO 
indicating the nature and value.  Statistical, analytical, math-
ematical, comparative, logical and descriptive methods of 
study were used.
Results and discussion
To determine DDD and compare the consumption of ali-
mentary tract and metabolism drugs for the period of 2009-
2013, the statistics data concerning the number of treated pa-
tients (patients with health insurance and other free treated 
by the state categories of citizens were involved), the number 
of bed/days and total annual quantities of medicines were 
used.  In figure 1 is presented consumption of parenteral 
form of drugs from Alimentary tract and metabolism group 
in natural indexes “grams” in EMI for the evaluated period.
From figure 1 we find that the main volume of consump-
tion of medicinal remedies of group A – Alimentary tract and 
metabolism as parenteral administration in natural indices 
is subgroup A12 Mineral supplements which increased the 
consumption volume gradually from 29 560 grams or 47% 
of all amount in 2009 to 42 495 grams or 63% of all amount 
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in 2013 consisting in a share of 43.8% during the evaluation 
period.  The second subgroup in placement of consump-
tion represents A11 “Vitamins”, with a decrease from 24409 
grams or 39% of all amounts in 2009, up to 14439 grams 
or 21% from amount in 2013 consisting in a share of 40.8% 
during the evaluation period.  The rest of subgroups: A02 
Drugs for acid-related disorders, A03 Drugs for functional 
gastrointestinal disorders, A05 Bile and liver therapy, A06 
Drugs for constipation problems and A16 Other alimentary 
tract and metabolism products consumed apart less than 
10%, together accounting 14% in 2009 and 16% in 2013. 
The parenteral consumption form in value indices “Lei” 
of drugs Alimentary tract and metabolism in EMI for the 
period of 2009–2013 is presented in table 1.
The consumption in value indices (lei) for the parenter-
al use more than 10% per year is represented by four sub-
groups: A02 Drugs for acid-related disorders, A03 Drugs for 
functional gastrointestinal disorders, A11 Vitamins and A12 
Mineral supplements and is 759 509 lei or 85.7% in 2009 and 
856  449 lei or 96.9% in 2013.  The rest of subgroups A05 
Bile and liver therapy and A16 Other alimentary tract and 
metabolism products consumption in 2009 amounted to 127 
034 lei or 14.3% in 2009 and 27 570 lei or 3.1% in 2013.
In the evaluated period a considerable increase was re-
corded for subgroups: A03 Drugs for acid-related disorders 
at 169 150 lei in 2009 to 223 484 lei in 2013 or by 32.2% and 
A12 Mineral supplements at 147 619 lei in 2009 to 254340 lei 
in 2013 or by 72.3 %.
The consumption of oral form of administration in natu-
ral indexes “grams” drugs of subgroups A Alimentary tract 
and metabolism in the period of 2009 – 2013 years is pre-
sented in figure 2.
From figure 2 it is clear that the main volume of con-
sumption of medical remedies for enteral administration of 
Alimentary tract and metabolism group in natural indices 
is drugs of subgroup A07 Antidiarrheals, intestinal antiin-
flamatory/antiinfective agents, which minimal annual quota 
changed from 48% or 23 170 grams in 2010 to maximal 85% 
Fig. 1.  Parenteral form consumption in natural indexes 
“grams” of drugs from Alimentary tract and metabolism 
group in Emergency Medicine Institute for the period from 
2009 to 2013.
Table 1
The parenteral consumption form in value indices “Lei” of drugs Alimentary tract 
 and metabolism used in the period of 2009 –2013
Years 2009 2010 2011 2012 2013
Pharmacotherapeutic groups/value indexes Lei Lei Lei Lei Lei
A02 Drugs for acid-related disorders 275306 346071 243018 359853 302621
A03 Drugs for functional gastrointestinal disorders 169150 172073 134006 75917 223484
A05 Bile and liver therapy 84256 89815 22226 8019 15610
A11 Vitamins 167434 75515 103520 84544 76004
A12 Mineral supplements 147619 157817 178154 237089 254340
A16A Other alimentary tract and metabolism products 42778 26420 29972 22189 11960
Total 886543 867711 710895 787610 884019
Percentage 100% 98,00% 80,00% 89,00% 100%
Fig. 2.  Oral form consumption in natural indexes “grams” 
of drugs from Alimentary tract and metabolism group in 
Emergency Medicine Institute for the period of 2009 – 2013.
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or 87 453 grams in 2012.  Despite considerable deviations 
in 2010 and 2012, the consumption of 48 923 grams in 2009 
differs slightly from the consumption of 47 685 grams in 
2013 that represents a small decrease of 2.5%. 
The second subgroup was placed after consumption vol-
ume A06 with the minimal annual quota of 8% in 2012 to 
maximal of 37% in 2010, and with the highest consumption 
of 18 240 grams in 2013.  The overall total consumption in the 
studied period for enteral form represents an increase from 
60 362 grams in 2009 to 77 786 grams in 2013 or by 29%.
Consumption of drugs from subgroups A Alimentary 
tract and metabolism in oral form in value indices “Lei” for 
the period of 2009 – 2013 years is presented in table 2.
As shown in table 2, the consumption value for enteral 
administration form in the evaluated period, with represen-
tative annual rate of more than 10% is represented by two 
subgroups A02 Drugs for acid-related disorders (from 2011 
to 2013) and A07 Antidiarrheals, intestinal antiinflamatory/
antiinfective agents, which in 2009 amounted to 89 675 lei or 
79.6%, and in 2013 constituted an amount of 126 876 lei or 
80%.  A considerable increase in consumption was for sub-
group A02, from 9 025 lei in 2009 to 87 012 lei in 2013 or by 
9.7 times.  A considerable decrease in consumption was for 
subgroup A07 from 80 650 lei in 2009 to 39 864 lei in 2013 
or by 2.02 times. 
Total consumption in value indices “Lei” of drugs from 
subgroups A Alimentary tract and metabolism for parenter-
al and oral use in EMI in the period of 2009 – 2013 years is 
presented in figure 3.
The main assessed indices of volume were determined 
during the consumption of medicinal remedies of three sub-
groups A02 Drugs for acid-related disorders, A03 Drugs for 
functional gastrointestinal disorders  and A12 Mineral sup-
plements which showed a consumption respectively in 2009 
of 284 331 lei (28.8%), 181 754 lei (17.2%), 148 047 lei (15%), 
the total 644 132 lei (64.47%) and in 2013 recorded 389 633 
lei (37.4%), 228 507 lei (21.9%), 258 245 lei (24.8%), with a 
total for the mentioned subgroups of 876 385 lei (84.0%). 
Each of listed subgroups marked an increase of 37%, 
25.8%, 74.5% respectively, or a total increase of 36.1%.  A 
considerable decrease in consumption recorded subgroups 
A05 Bile and liver therapy, A11 Vitamins and A16 Other ali-
mentary tract and metabolism products, which in 2009 had 
a total consumption of 298 824 lei or 29.9% for all amount, 
and in 2013 recorded respectively a total of 110 996 lei or 
10.7% for all amount, or a total decrease for the mentioned 
subgroups of 62.8%.  Nevertheless, total consumption of 
drugs from Alimentary tract and metabolism group during 
the evaluation period marked an increase of 104.4% in 2013 
compared to 2009.
The parenteral and oral form consumption in natural in-
dices “grams” of drugs from Alimentary tract and metabo-
Table 2
The oral form consumption in value indices “Lei” of drugs from Alimentary tract  
and metabolism group for oral use in the period of 2009–2013
Years 2009 2010 2011 2012 2013
Pharmacotherapeutic groups/values indexes/percentage Lei Lei Lei Lei Lei
A02 Drugs for acid-related disorders 9025 4820 54223 17789 87012
A03 Drugs for functional gastrointestinal disorders 12604 3667 10455 2925 3963
A05 Bile and liver therapy 3646 1685 5824 2754 5023
A06A Drugs for constipation problems 5523 14152 5798 6209 16378
A07 Antidiarrheals, intestinal antiinflamatory/antiinfective agents 80650 24735 61257 50839 39864
A12 Mineral suppliments 428 2339 3018 1906 3905
A16 Other alimentary tract and metabolism products 773 2582 889 1353 2399
Total 112649 53980 141464 83775 158544
Percentage 100% 48% 126% 74% 141%
Fig. 3.  Parenteral and oral consumption in value indices “Lei” 
of drugs from Alimentary tract and metabolism group in 
Emergency Medicine Institute in the period of 2009 – 2013.
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consumption for the period under review has been seen in 
subgroup A12 Mineral supplements from 29 690 grams to 
46 832 grams or by 57.8%, and less stable for subgroup A03 
Drugs for functional gastrointestinal disorders from 3 821 
grams up to 6 389 grams or by 67.2% and A06 Drugs for 
constipation problems from 6 200 grams up to 18 240 grams 
or by 2.94 times.  At the same time, a decrease in consump-
tion during the mentioned period records subgroup A11 
Vitamins, from 24 409 grams to 14 439 grams or by 41%. 
Total consumption of all subgroups in mentioned period has 
increased by 18%.
To assess the consumption of defined daily doses of 
drugs recommended by the WHO in case of absence of the 
drugs in the list of WHO was defined and used the notion 
of defined daily doses by the Emergency Medicine Institute 
(EMI) with the abbreviations DDDEMI.  These doses were 
determined after the evaluation from 300 to 500 cases treat-
ed in different profile sections and different time periods.  A 
list with nomenclature of drugs with DDD and DDDEMI 
used for the evaluation of medicines is presented in table 3.
Table 3
Defined Daily Doses determined in Emergency Medicine Institute
International names of drugs or their composition Route DDD (EMI)
A ALIMENTARY TRACT AND METABOLISM
A02A ANTACIDS
Al. hydroxidum 218 mg + Mg hydroxidum 75 mg + Benzocainum 109 mg/5 ml O 4824
Aluminii hydroxidum 218 mg + Magnesii hydroxidum 75 mg/5 ml O 3516
Aluminii hydroxidum 3,5 g + Magnesii hydroxidum + 4 g/100 ml O 4500
Aluminii hydroxidum 400 mg + Magnesii hydroxidum 400 mg O 4800
Aluminii hydroxidum/Magnesii carbonas gel  450mg+Magnesii hydroxidum 300 mg O 5250
Omeprazolum 20 mg + Clarithromycinum 250 mg + Tinidazolum 500 mg O 1540
A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Platyphyllini hydrotartras 0,2% 1 ml P 6
A05B LIVER THERAPY, LIPOTROPICS
Essential phaspholipids 50 mg, Pyridoxini hydrochloridum 0,5 mg, Cyanocobalaminum 2 mcg, Natrii D-pantothenas 
0,3 mg, Nicotinamidum 5 mg, Vehiculum ad 1 ml.
P 750
Phospholipidum hipotalamus 300 mg O 1800
Argininum 12,5 g + Sorbitolum 25 g P 2500
Extractum chole 25mg+Extractum Cynarae scolimus 25mg+Curcumae longae pulvis+50 mg O 3000
Kalii orotas 500 mg O 1250
Silymarinum 35 mg O 300
A06A DRUGS FOR CONSTIPATION
Cassia acutifolia 70 mg O 140
A07C ELECTROLYTES WITH CARBOHYDRATES
Hidroreg  18.9g O 18900
A11D VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12
Cyanocobalaminum 50 mg + Pyridoxinum 50 mg + Thiaminum 1 mg P 101
lism group in EMI in the period of 2009 – 2013 years is pre-
sented in figure 4.
As it could be seen from figure 4, a steady increase in 
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To determine the annual number of DDD in the peri-
od 2009–2013, the annual consumption in natural indices 
(grams), separate for each parenteral and enteral form was 
split to medicinal remedies DDD recommended by WHO, 
and respectively in their absence to the DDD (EMI) to ob-
tain further amounts for each of the subgroups.  The total of 
these data is shown in table 4.
The DDD consumption for some subgroups in some 
years varied considerably, but excluding the years when 
consumption is minimal and least compatible, annual ave-
rage for A02 Drugs for acid-related disorders is 35423, A03 
Drugs for functional gastrointestinal disorders is 64297, A05 
Bile and liver therapy is 2483, A06 Drugs for constipation 
A11J OTHER VITAMIN PRODUCTS, COMBINATIONS
Cyanocobalaminum (B12) 0,5 mg, Nicotinamidum ( PP) 20 mg, Cocarboxilaza (coenzim of vit. B1) 50 mg, Adenozintri-
fosfat disodic trihidrat (ATP) 10 mg
P 81
Magnesii lactas + Magnesii pidolas + Pyridoxinum O 2850
A12B POTASSIUM
Kalii chloridum  4% 10 ml P 1600
Kalii aspartas + Magnesii aspartas 452 mg + 400 mg/10 ml P 1704
Kalii aspartas + Magnesii aspartas 175 mg + 175 mg O 1050
Kalii aspartas + Magnesii aspartas 158 mg + 140 mg O 998
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
Ademetioninum 400 mg P 600
Ademetioninum 400 mg O 800
Note: O – oral, P – parenteral. 
Table 4
Parenteral and oral form consumption in DDD, of subgroups Alimentary tract 
 and metabolism drugs in Emergency Medicine Institute in the period of 2009–2013
Administered forms Measure unit A02 A03 A05 A07 A11 A12 A16
2009
Parenteral (WHO) DDD 19947 49477 219 2083 317 60
Parenteral (EMI) DDD 0 6650 115 110 331
Oral  (WHO) DDD 7921 2339 600 334 1170
Oral  (EMI) DDD 444 0 57 230
Total 28312 58466 657 2193 878 1230
2010
Parenteral (WHO) DDD 23009 76147 0 0 82769 242 831
Parenteral (EMI) DDD 0 9143 1160 0 425 18535
Oral  (WHO) DDD 13275 1337 0 3289 
Oral  (EMI) DDD 395 0 542 4684
Total DDD 36679 86627 1702 3289 83614 23461  831 
2011
Parenteral (WHO) DDD 9630 55623 7241 377 1434
Parenteral (EMI) DDD 0 10380 12 20346 7
Oral  (WHO) DDD 24806 1387 17 29134
Oral  (EMI) DDD 704 0 2720 29 5657 120
Total DDD 35140 67390 2737 29163 7415 26380 1561
2012
Parenteral (WHO) DDD 11514 46761 0 7241 20486 236
Parenteral (EMI) DDD 0 9627 180 12 129 13
Oral  (WHO) DDD 22898 1397 0 2918
Oral  (EMI) DDD 931 0  183 146 784 10
Total DDD 35343 57785 363 3064 7415 21399 259 
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problems is 3164, A07 Antidiarrheals, intestinal antiinflam-
atory/antiinfective agents is 22835, A11 Vitamins is 99777, 
A12 Mineral supplements is 31509, A16 Other alimentary 
tract and metabolism products is 1396 DDD. 
Total annual consumption in DDD of drugs group A Ali-
mentary tract and metabolism for parenteral and oral use in 
EMI in the period of 2009 – 2013 years is shown in table 5.
From total number of DDD consisting in each subgroup 
the parenteral form (DDD and DDD(EMI)) represented in 
sequence by years are 85.7% in 2009, 83.6% in2010; 77.5% 
in 2011; 76.7% in2012; 72.8% in 2013 and oral form (DDD 
and DDD(EMI)) respectively 14.3%; 16.4%; 22.5%; 23.3% 
and 27.2%.
To determine the DDD/1000 during the evaluated peri-
od, was taken into account the following data: the number of 
patients treated in the institution (except those who have no 
insurance policy and pay for treatment), which in 2009 was 
20 946 patients, the median duration of treatment 8.62 days, 
2013
Parenteral (WHO) DDD 13346 37928 0 77674 418 37
Parenteral (EMI) DDD 0 8957 980 550 18739
Oral  (WHO) DDD 27552 4332 958 17271 20
Oral  (EMI) DDD 742 57 1035 4130
Total DDD 41640 51217 3010 18306 78705 23287 57 
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Table 5
Total annual parenteral and oral form consumption in DDD of Alimentary tract 
and metabolism drugs in Emergency Medicine Institute in the period of 2009 – 2013
Administered form Measure unit 2009 2010 2011 2012 2013
Parenteral (WHO) DDD 71884 182998 203247 86238 129403
Parenteral (EMI) DDD 7091 29263 31463 9961 29226
Oral (WHO) DDD 12269 35067 58662 27333 53087
Oral (EMI) DDD 876 6621 9645 1913 6165
Total 92120 253949 303017 125445 217881
Fig. 5. Total annual parenteral and oral form consumption in DDD/1000 of subgroups alimentary tract and 
metabolism drugs in Emergency Medicine Institute in the period of 2009 – 2013.
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which amounts to 188 762 days/bed; in 2010 their number 
was 21 341, and the median duration of treatment 8.64 days, 
which amounts to 191  556 bed/days; in 2011 was 19 913 
patients and the median duration of treatment 8.66 days, 
which amounts to 186 246 bed/days; 2012 was 20 664 and 
the median duration of treatment 8.82 days, which amounts 
to 199 816 bed/days, and, in 2013 respectively was 20 830 
with a median treatment duration 7.8 days, which amounts 
to 193 019 bed/days [16].
As one can see from figure 5 in the investigation period 
the consumption of DDD/1000 more than 100 units were 
registered for the following subgroups: A02 Drugs for acid-
related disorders, A03 Drugs for functional gastrointestinal 
disorders, A07 Antidiarrheals, intestinal antiinflamatory/
antiinfective agents, A11 Vitamins and A12 Mineral supple-
ments.  The consumption of DDD/1000 of oral form for sub-
groups A02 Drugs for acid-related disorders and A07 An-
tidiarrheals, intestinal antiinflamatory/antiinfective agents 
have been constantly increasing over the evaluated period 
from 44.4 and 1.8 units in 2009 to respectively 146.5 and 94.8 
units in 2013.
The total annual parenteral and oral form consumption 
of DDD/1000 of drugs Alimentary tract and metabolism 
group in EMI, for the period of 2009 – 2013 is presented in 
figure 6.
Fig. 6.  Total annual parenteral and oral form consumption 
in DDD/1000 of alimentary tract and metabolism drugs in 
Emergency Medicine Institute in the period of 2009 – 2013.
A considerable difference between the total DDD con-
sumed per 1 000 occupied bed/days for the period under 
evaluation can be observed from figure 6.  And, if that con-
sumption in 2009 was considered as 1 unit, then this report 
for 2010 would be 1: 2.75, for 2011 = 1: 3.33, for 2012 = 1: 1.3, 
for 2013 = 1: 2.31.  To assess the cost of one DDD/1000 per 
year, we divided the value in “Lei” spent by the number of 
DDD consumed and multiplied by the number of DDD/1000 
occupied bed/days determined per year.  So in 2009 the cost 
of DDD/1000 was 5180.7 lei (999 195 lei: 94 120 x 488); in 
2010 was 4878.0 lei (921 691 lei: 253 949 x 1344); in 2011was 
4571.2 lei (851 359 lei: 303 017 x 1627); in 2012 was 4397.1 
lei (871 386 lei: 125 445 x 633) and in 2013 was 5397.5 lei 
(1 042 562 lei: 217 881 x 1128).
Conclusions
1. The obtained data reveals that from 3 basic characte-
ristics of drug consumption [index value, natural indicators 
(grams), natural indicators DDD], DDD is the most objective 
and can be considered as the cornerstone for making decisions 
on determining the needs and organization of rational use 
of medicines, that in practice means implementation of the 
“Drug Statistics Methodology” of WHO Collaborating Centre 
in the Republic of Moldova, first of all in hospital institutions.
2. Taking as a starting point 2009 year the overall assessed
consumption of medicinal remedies was presented in:
· index value (lei) of 999 195 lei, the percentage in 2010
amounted to 92.3% (921 691 lei), in 2011 to 85.2% (851
359 lei), in 2012 to 87.2% (871 386 lei) and in 2013 to
104.4% (1042562 lei), or a variation for the evaluated
period of 19.2% (from -14,8% to 4.4%);
· natural indicators (grams) of 123479 grams in 2009,
which in 2010 amounted to 89% (109510 grams),
in 2011 to 110.7% (136712 grams), in 2012 to133.6
% (165019 grams)  and in 2013 to 117.5% (145 092
grams) or a variation for the evaluated period of 44.6%
(from - 11% to 33.6%).
3. Total number of DDD consisting in each subgroup is
94 120 in 2009, to 253 949 in 2010, to 303 017 in 2011, to 125 
445 in 2012 and to 217 881 in 2013, of these totals:
· The parenteral form (DDD and DDDEMI) represent-
ed in sequence by years is 85.7% or 78975, 83.6% or
212 261; 77.5% or 234 710; 76.7% or 96 199; 72.8% or
158 629;
· The oral form (DDD and DDDEMI) respectively
14.3% or 13 145; 16.4% or 41688; 22.5% or 68 307;
23.3% 29 246 and 27.2% 59 252.
4. The annual average consumption was recorded for:
A02 Drugs for acid-related disorders of 35423 DDD, A03 
Drugs for functional gastrointestinal disorders of 64297 
DDD, A05 Bile and liver therapy of 2483 DDD, A06 Drugs 
for constipation problems of 3164 DDD, A07 Antidiarrheals, 
intestinal antiinflamatory/antiinfective agents of 22835 DDD, 
A11 Vitamins of 99777 DDD, A12 Mineral supplements of 
31509 DDD and A16 Other alimentary tract and metabolism 
products of 1396 DDD. 
5. The number of consumption DDD/1000 occupied bed
days in the period under evaluation was:
· 488 in 2009, 1344 in 2010 or an increase of 275%,
1627 in 2011 or an increase of 333%, 633 in 2012 or
an increase of 130% and 1128 in 2013 or an increase of
231%.  The variation in the evaluated period was from
minimal 1.3 times to maximal 3.3 times;
· the cost of one DDD/1000 that was respectively 5180.7
lei in 2009, decreases to 4878.0 lei in 2010, 4571.2 lei in
2011and 4397.1 lei in 2012, respectively and increases
to 5397.5 lei in 2013.
6. In order to fully assess drug consumption in DDD for
medicinal remedies that WHO has not published, DDD based 
on the data of Emergency Medicine Institute were determined 
for 24 drugs. 
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